Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4897)
All Articles published online
|
Dec 14, 2008 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sirica AE. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol 2008; 14(46): 7033-7058 [PMID: 19084911 DOI: 10.3748/wjg.14.7033] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i46/7033.htm |
| Number | Citing Articles |
| 1 |
Donatella Marino, Francesco Leone, Giuliana Cavalloni, Celeste Cagnazzo, Massimo Aglietta. Biliary tract carcinomas: From chemotherapy to targeted therapy. Critical Reviews in Oncology/Hematology 2013; 85(2): 136 doi: 10.1016/j.critrevonc.2012.06.006
|
| 2 |
Cristina Quintavalle, Katharina Burmeister, Salvatore Piscuoglio, Luca Quagliata, Eva Karamitopoulou, Romina Sepe, Alfredo Fusco, Luigi M. Terracciano, Jesper B. Andersen, Pierlorenzo Pallante, Matthias S. Matter. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Molecular Carcinogenesis 2017; 56(9): 2146 doi: 10.1002/mc.22671
|
| 3 |
Zong-Long Li, Jia-Lu Chen, Yue Tang, De-Long Qin, Zhao-Hui Tang. MASLD: an emerging factor in the pathophysiology and clinical management of ICC. Hepatoma Research 2024; doi: 10.20517/2394-5079.2024.63
|
| 4 |
Boris R.A. Blechacz, Gregory J. Gores. Molecular Genetics of Liver Neoplasia. 2010; : 75 doi: 10.1007/978-1-4419-6082-5_5
|
| 5 |
Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo. Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. Gastrointestinal Disorders 2020; 3(1): 1 doi: 10.3390/gidisord3010001
|
| 6 |
Massimiliano Berretta, Carla Cavaliere, Lara Alessandrini, Brigida Stanzione, Gaetano Facchini, Luca Balestreri, Tiziana Perin, Vincenzo Canzonieri. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget 2017; 8(8): 14192 doi: 10.18632/oncotarget.13929
|
| 7 |
L. Jödicke, L. Zender, N. P. Malek. Personalisierte Therapie des cholangiozellulären Karzinoms. Der Internist 2020; 61(2): 170 doi: 10.1007/s00108-019-00723-w
|
| 8 |
Ioannis Ntanasis-Stathopoulos, Diamantis I Tsilimigras, Maria Gavriatopoulou, Dimitrios Schizas, Timothy M Pawlik. Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Review of Anticancer Therapy 2020; 20(9): 765 doi: 10.1080/14737140.2020.1807333
|
| 9 |
Aslam Ejaz, Jordan M. Cloyd, Timothy M. Pawlik. Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology 2020; 27(2): 552 doi: 10.1245/s10434-019-07873-z
|
| 10 |
Sumera I Ilyas, Mitesh J. Borad, Tushar Patel, Gregory J. Gores. Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities. Seminars in Liver Disease 2014; 34(04): 456 doi: 10.1055/s-0034-1394144
|
| 11 |
Pasquale Lombardi, Donatella Marino, Elisabetta Fenocchio, Giovanna Chilà, Massimo Aglietta, Francesco Leone. Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opinion on Emerging Drugs 2018; 23(1): 63 doi: 10.1080/14728214.2018.1444749
|
| 12 |
Amir A Rahnemai-Azar, Pallavi Pandey, Ihab Kamel, Timothy M Pawlik. Monitoring Outcomes in Intrahepatic Cholangiocarcinoma Patients Following Hepatic Resection. Hepatic Oncology 2016; 3(4): 223 doi: 10.2217/hep-2016-0009
|
| 13 |
Angela Lamarca, Salvatore Galdy, Jorge Barriuso, Sharzad Moghadam, Elizabeth Beckett, Jane Rogan, Alison Backen, Catherine Billington, Mairéad G. McNamara, Richard A. Hubner, Angela Cramer, Juan W. Valle, Aamir Ahmad. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLOS ONE 2018; 13(10): e0206007 doi: 10.1371/journal.pone.0206007
|
| 14 |
Mingxun Wang, Ziyan Chen, Pengyi Guo, Yi Wang, Gang Chen. Therapy for advanced cholangiocarcinoma: Current knowledge and future potential. Journal of Cellular and Molecular Medicine 2021; 25(2): 618 doi: 10.1111/jcmm.16151
|
| 15 |
Qi Zhang, Tao Jing, Xiuxiang Cui, Lina Zhao. Rational Molecular Profiling of Receptor-Associated Late Transducer Peptide Selectivity Across Her/Rtk Kinases. International Journal of Peptide Research and Therapeutics 2021; 27(3): 1945 doi: 10.1007/s10989-021-10223-x
|
| 16 |
Tadashi Terada. Stem cells in the development and differentiation of the human adrenal glands. Microscopy Research and Technique 2015; 78(1): 59 doi: 10.1002/jemt.22445
|
| 17 |
Zichen Zhang, Regina A. Oyesanya, Deanna J. W. Campbell, Jorge A. Almenara, Jennifer L. DeWitt, Alphonse E. Sirica. Preclinical Assessment of Simultaneous Targeting of Epidermal Growth Factor Receptor (ERBB1) and ERBB2 as a Strategy for Cholangiocarcinoma Therapy†,‡. Hepatology 2010; 52(3): 975 doi: 10.1002/hep.23773
|
| 18 |
Jesper B Andersen, Snorri S Thorgeirsson. A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepatic Oncology 2014; 1(1): 143 doi: 10.2217/hep.13.4
|
| 19 |
Jason K. Sicklick, Paul T. Fanta. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. 2017; : 150 doi: 10.1016/B978-0-323-34062-5.00122-9
|
| 20 |
Jinxin Chen, Linbo Guan, Ping Fan, Xinghui Liu, Rui Liu, Yu Liu, Huai Bai. In vitro study of the effects of DC electric fields on cell activities and gene expression in human choriocarcinoma cells. Electromagnetic Biology and Medicine 2021; 40(1): 49 doi: 10.1080/15368378.2020.1846555
|
| 21 |
Amir A. Rahnemai-Azar, Allison B. Weisbrod, Mary Dillhoff, Carl Schmidt, Timothy M. Pawlik. Intrahepatic cholangiocarcinoma: current management and emerging therapies. Expert Review of Gastroenterology & Hepatology 2017; 11(5): 439 doi: 10.1080/17474124.2017.1309290
|
| 22 |
Jiang Xie, Dongfang Lu, Jiaxin Li, Jiao Wang, Yong Zhang, Yanhui Li, Qing Nie. Kernel differential subgraph reveals dynamic changes in biomolecular networks. Journal of Bioinformatics and Computational Biology 2018; 16(01): 1750027 doi: 10.1142/S0219720017500275
|
| 23 |
Mickaël Di‐Luoffo, Sophie Pirenne, Thoueiba Saandi, Axelle Loriot, Claude Gérard, Nicolas Dauguet, Fátima Manzano‐Núñez, Natália Alves Souza Carvalhais, Florence Lamoline, Sabine Cordi, Katarzyna Konobrocka, Vitaline De Greef, Mina Komuta, Georg Halder, Patrick Jacquemin, Frédéric P. Lemaigre. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin‐4 in Tumor Progression. Hepatology 2021; 74(3): 1445 doi: 10.1002/hep.31834
|
| 24 |
Tse-Ching Chen, Yi-Yin Jan, Ta-Sen Yeh. K-ras Mutation is Strongly Associated with Perineural Invasion and Represents an Independent Prognostic Factor of Intrahepatic Cholangiocarcinoma after Hepatectomy. Annals of Surgical Oncology 2012; 19(S3): 675 doi: 10.1245/s10434-012-2224-7
|
| 25 |
Ruizhen Liu, Yi Kong, Pengbo Sun, Faliang Li, Xiaopeng Shi. Correlation between methylation of the caveolin‐1 gene and of caveolin‐1 messenger ribonucleic acid, and protein levels and human epidermal growth factor receptor 2 protein expression in adenocarcinomas of the esophagogastric junction. Precision Radiation Oncology 2019; 3(1): 8 doi: 10.1002/pro6.61
|
| 26 |
Karin Komposch, Maria Sibilia. EGFR Signaling in Liver Diseases. International Journal of Molecular Sciences 2015; 17(1): 30 doi: 10.3390/ijms17010030
|
| 27 |
Aileen Deng, Steven Cohen. Primary and Metastatic Liver Tumors. 2018; : 137 doi: 10.1007/978-3-319-91977-5_11
|
| 28 |
Hidenori Sahashi, Akihisa Kato, Michihiro Yoshida, Kazuki Hayashi, Itaru Naitoh, Yasuki Hori, Makoto Natsume, Naruomi Jinno, Kenta Kachi, Go Asano, Tadashi Toyohara, Yusuke Kito, Sudhakar Ammanamanchi, Hiromi Kataoka. Urolithin A targets the AKT/WNK1 axis to induce autophagy and exert anti-tumor effects in cholangiocarcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.963314
|
| 29 |
Ling Li, Baofeng Lian, Chao Li, Wei Li, Jing Li, Yuannv Zhang, Xianghuo He, Yixue Li, Lu Xie, Frank Emmert-Streib. Integrative Analysis of Transcriptional Regulatory Network and Copy Number Variation in Intrahepatic Cholangiocarcinoma. PLoS ONE 2014; 9(6): e98653 doi: 10.1371/journal.pone.0098653
|
| 30 |
Takuya Kitamura, Kevin Connolly, Lynnsie Ruffino, Tetsuo Ajiki, Aline Lueckgen, John DiGiovanni, Kaoru Kiguchi. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. Journal of Hepatology 2012; 57(1): 84 doi: 10.1016/j.jhep.2012.01.018
|
| 31 |
B. N. Gurmikov, Yu. A. Kovalenko, V. A. Vishnevsky, A. V. Chzhao. Molecular genetic aspects of intrahepatic cholangiocarcinoma: literature review. Advances in molecular oncology 2019; 6(1): 37 doi: 10.17650/2313-805X-2019-6-1-37-43
|
| 32 |
Dong Kuang, Guo-Ping Wang. Hilar cholangiocarcinoma: Pathology and tumor biology. Frontiers of Medicine in China 2010; 4(4): 371 doi: 10.1007/s11684-010-0130-6
|
| 33 |
Un-Jung Yun, Jee Young Sung, Seog-Yun Park, Sang-Kyu Ye, Jaegal Shim, Jae-Seon Lee, Masahiko Hibi, Young-Ki Bae, Yong-Nyun Kim. Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway. Cell Death & Disease 2017; 8(2): e2621 doi: 10.1038/cddis.2017.50
|
| 34 |
Manuela Gatto, Maria Consiglia Bragazzi, Rossella Semeraro, Cristina Napoli, Raffaele Gentile, Alessia Torrice, Eugenio Gaudio, Domenico Alvaro. Cholangiocarcinoma: Update and future perspectives. Digestive and Liver Disease 2010; 42(4): 253 doi: 10.1016/j.dld.2009.12.008
|
| 35 |
Peter L. Labib, George Goodchild, Stephen P. Pereira. Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-5391-0
|
| 36 |
Toru Kawamoto, Kazunori Ishige, Melanie Thomas, Yoriko Yamashita-Kashima, Sei Shu, Nobuyuki Ishikura, Shunichi Ariizumi, Masakazu Yamamoto, Kunihiko Kurosaki, Junichi Shoda. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. Journal of Gastroenterology 2015; 50(4): 467 doi: 10.1007/s00535-014-0984-5
|
| 37 |
Pattaya Seeree, Phorutai Pearngam, Supeecha Kumkate, Tavan Janvilisri. An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. International Journal of Genomics 2015; 2015: 1 doi: 10.1155/2015/179528
|
| 38 |
T.M. Gilbert, L. Randle, M. Quinn, O. McGreevy, L. O’leary, R. Young, R. Diaz-Neito, R.P. Jones, B. Greenhalf, C. Goldring, S. Fenwick, H. Malik, D.H. Palmer. Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management. European Journal of Surgical Oncology 2024; : 108352 doi: 10.1016/j.ejso.2024.108352
|
| 39 |
Wen-Sheng Wu, Chin-Hsien Ling, Ming-Che Lee, Chuan-Chu Cheng, Rui-Fang Chen, Chen-Fang Lin, Ren-In You, Yen-Cheng Chen. Targeting Src-Hic-5 Signal Cascade for Preventing Migration of Cholangiocarcinoma Cell HuCCT1. Biomedicines 2022; 10(5): 1022 doi: 10.3390/biomedicines10051022
|
| 40 |
Qi-Bing Wu, Guo-Ping Sun. Expression of COX-2 and HER-2 in colorectal cancer and their correlation. World Journal of Gastroenterology 2015; 21(20): 6206-6214 doi: 10.3748/wjg.v21.i20.6206
|
| 41 |
Rebecca A. Rozich, David R. Mills, Kate E. Brilliant, Helen M. Callanan, DongQin Yang, Umadevi Tantravahi, Douglas C. Hixson. Accumulation of neoplastic traits prior to spontaneous in vitro transformation of rat cholangiocytes determines susceptibility to activated ErbB-2/Neu. Experimental and Molecular Pathology 2010; 89(3): 248 doi: 10.1016/j.yexmp.2010.07.005
|
| 42 |
Ruben Jansen, Birte Moehlendick, Christoph Bartenhagen, Csaba Tóth, Nadja Lehwald, Nikolas H. Stoecklein, Wolfram T. Knoefel, Anja Lachenmayer. ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-28941-6
|
| 43 |
Pedro M. Rodrigues, Paula Olaizola, Nuno A. Paiva, Irene Olaizola, Alona Agirre-Lizaso, Ana Landa, Luis Bujanda, Maria J. Perugorria, Jesus M. Banales. Pathogenesis of Cholangiocarcinoma. Annual Review of Pathology: Mechanisms of Disease 2021; 16(1): 433 doi: 10.1146/annurev-pathol-030220-020455
|
| 44 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2016; : 1 doi: 10.1007/978-3-319-26587-2_31-1
|
| 45 |
Abigail Zabron, Robert J. Edwards, Shahid A. Khan. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Disease Models & Mechanisms 2013; 6(2): 281 doi: 10.1242/dmm.010561
|
| 46 |
Jesper B. Andersen, Bart Spee, Boris R. Blechacz, Itzhak Avital, Mina Komuta, Andrew Barbour, Elizabeth A. Conner, Matthew C. Gillen, Tania Roskams, Lewis R. Roberts, Valentina M. Factor, Snorri S. Thorgeirsson. Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. Gastroenterology 2012; 142(4): 1021 doi: 10.1053/j.gastro.2011.12.005
|
| 47 |
Svetlana V. Chulkova, Vitaly I. Loginov, Danil V. Podluzhny, Angelina V. Egorova, Dmitry G. Semichev, Irina A. Gladilina, Nikolai E. Kudashkin. The role of molecular genetic factors in the development of cholangiocellular cancer: A review. Journal of Modern Oncology 2022; 24(2): 164 doi: 10.26442/18151434.2022.2.201426
|
| 48 |
Amir A. Rahnemai-Azar, Allison Weisbrod, Mary Dillhoff, Carl Schmidt, Timothy M. Pawlik. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surgical Oncology 2017; 26(2): 125 doi: 10.1016/j.suronc.2016.12.009
|
| 49 |
Alice Boilève, Marc Hilmi, Matthieu Delaye, Annemilaï Tijeras-Raballand, Cindy Neuzillet. Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. Cancers 2021; 13(11): 2708 doi: 10.3390/cancers13112708
|
| 50 |
Cyril Dalmasso, Wassila Carpentier, Catherine Guettier, Sophie Camilleri-Broët, Wyllians Vendramini Borelli, Cedália Rosane Campos dos Santos, Denis Castaing, Jean-Charles Duclos-Vallée, Philippe Broët. Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1111-6
|
| 51 |
Elisa Lozano, Paula Sanchon-Sanchez, Ana Morente-Carrasco, Luis Miguel Chinchilla-Tábora, José L. Mauriz, Paula Fernández-Palanca, Jose J. G. Marin, Rocio I. R. Macias. Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity. Cells 2023; 12(8): 1141 doi: 10.3390/cells12081141
|
| 52 |
Audrey Clapéron, Martine Mergey, Lynda Aoudjehane, Thanh Huong Nguyen Ho-Bouldoires, Dominique Wendum, Aurélie Prignon, Fatiha Merabtene, Delphine Firrincieli, Christèle Desbois-Mouthon, Olivier Scatton, Filomena Conti, Chantal Housset, Laura Fouassier. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology 2013; 58(6): 2001 doi: 10.1002/hep.26585
|
| 53 |
Amir A. Rahnemai-Azar, Arezou Abbasi, Alexandra W. Acher, Sharon M. Weber, Timothy M. Pawlik. Emerging pathways for precision medicine in management of cholangiocarcinoma. Surgical Oncology 2020; 35: 47 doi: 10.1016/j.suronc.2020.08.008
|
| 54 |
Ning Jin, Laith Abushahin. Intrahepatic Cholangiocarcinoma. 2019; : 107 doi: 10.1007/978-3-030-22258-1_8
|
| 55 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2017; : 605 doi: 10.1007/978-3-319-26956-6_31
|
| 56 |
|
| 57 |
S.V. Chulkova, V.I. Loginov, D.V. Podluzhnyi, A.V. Egorova, A.Yu. Syskova, D.G. Semichev, I.A. Gladilina, N.E. Kudashkin. The role of molecular genetic factors in the development of cholangiocellular carcinoma. Arkhiv patologii 2022; 84(3): 76 doi: 10.17116/patol20228403176
|
| 58 |
Alice Boilève, Loïc Verlingue, Antoine Hollebecque, Valérie Boige, Michel Ducreux, David Malka. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opinion on Investigational Drugs 2021; 30(4): 401 doi: 10.1080/13543784.2021.1896703
|
| 59 |
Hasaya Dokduang, Wassana Jamnongkarn, Bundit Promraksa, Manida Suksawat, Sureerat Padthaisong, Malinee Thanee, Jutarop Phetcharaburanin, Nisana Namwat, Sakkarn Sangkhamanon, Attapol Titapun, Narong Khuntikeo, Poramate Klanrit, Watcharin Loilome. <p>In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines</p>. Drug Design, Development and Therapy 2020; : 2319 doi: 10.2147/DDDT.S250061
|
| 60 |
Sandra Pavicevic, Sophie Reichelt, Deniz Uluk, Isabella Lurje, Cornelius Engelmann, Dominik P. Modest, Uwe Pelzer, Felix Krenzien, Nathanael Raschzok, Christian Benzing, Igor M. Sauer, Sebastian Stintzing, Frank Tacke, Wenzel Schöning, Moritz Schmelzle, Johann Pratschke, Georg Lurje. Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers 2022; 14(4): 1026 doi: 10.3390/cancers14041026
|
| 61 |
Apiwit Sae-fung, Apiwat Mutirangura, Siriporn Jitkaew. Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Frontiers in Immunology 2023; 13 doi: 10.3389/fimmu.2022.1051273
|
| 62 |
Oded Jacobi, Jeffrey S. Ross, Tal Goshen-Lago, Riad Haddad, Assaf Moore, Aaron Sulkes, Baruch Brenner, Irit Ben-Aharon. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. Oncology Research and Treatment 2021; 44(1-2): 20 doi: 10.1159/000511919
|
| 63 |
Fan Zhang, Lianhong Li, Xingwu Yang, Bo Wang, Jinyao Zhao, Shilun Lu, Xiaotang Yu. Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3’-methyl-4 dimethylaminoazobenzene in rats. Journal of Toxicologic Pathology 2015; 28(2): 79 doi: 10.1293/tox.2014-0047
|
| 64 |
Amir A. Rahnemai-Azar, Timothy M. Pawlik. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development. Expert Opinion on Investigational Drugs 2021; 30(4): 419 doi: 10.1080/13543784.2021.1897103
|
| 65 |
Tadashi Terada. Huge clusters of embryonic stem cells in human embryos: A morphologic study. Microscopy Research and Technique 2014; 77(10): 825 doi: 10.1002/jemt.22405
|
| 66 |
Michela Squadroni, Luca Tondulli, Gemma Gatta, Stefania Mosconi, Giordano Beretta, Roberto Labianca. Cholangiocarcinoma. Critical Reviews in Oncology/Hematology 2017; 116: 11 doi: 10.1016/j.critrevonc.2016.11.012
|
| 67 |
Giuseppe Tonini, Vladimir Virzì, Maria Elisabetta Fratto, Bruno Vincenzi, Daniele Santini. Targeted Therapy in Biliary Tract Cancer: 2009 Update. Future Oncology 2009; 5(10): 1675 doi: 10.2217/fon.09.130
|
| 68 |
Alice Boilève, Marc Hilmi, Cristina Smolenschi, Michel Ducreux, Antoine Hollebecque, David Malka. Immunotherapy in Advanced Biliary Tract Cancers. Cancers 2021; 13(7): 1569 doi: 10.3390/cancers13071569
|
| 69 |
Jesus M. Banales, Jose J. G. Marin, Angela Lamarca, Pedro M. Rodrigues, Shahid A. Khan, Lewis R. Roberts, Vincenzo Cardinale, Guido Carpino, Jesper B. Andersen, Chiara Braconi, Diego F. Calvisi, Maria J. Perugorria, Luca Fabris, Luke Boulter, Rocio I. R. Macias, Eugenio Gaudio, Domenico Alvaro, Sergio A. Gradilone, Mario Strazzabosco, Marco Marzioni, Cédric Coulouarn, Laura Fouassier, Chiara Raggi, Pietro Invernizzi, Joachim C. Mertens, Anja Moncsek, Sumera I. Ilyas, Julie Heimbach, Bas Groot Koerkamp, Jordi Bruix, Alejandro Forner, John Bridgewater, Juan W. Valle, Gregory J. Gores. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology 2020; 17(9): 557 doi: 10.1038/s41575-020-0310-z
|
| 70 |
D Sia, V Tovar, A Moeini, J M Llovet. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013; 32(41): 4861 doi: 10.1038/onc.2012.617
|
| 71 |
Sumera I. Ilyas, Gregory J. Gores. Emerging molecular therapeutic targets for cholangiocarcinoma. Journal of Hepatology 2017; 67(3): 632 doi: 10.1016/j.jhep.2017.03.026
|
| 72 |
Jesper B. Andersen. Molecular pathogenesis of intrahepatic cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 2015; 22(2): 101 doi: 10.1002/jhbp.155
|
| 73 |
Alphonse E. Sirica, Catherine I. Dumur, Deanna J.W. Campbell, Jorge A. Almenara, Olorunseun O. Ogunwobi, Jennifer L. Dewitt. Intrahepatic Cholangiocarcinoma Progression: Prognostic Factors and Basic Mechanisms. Clinical Gastroenterology and Hepatology 2009; 7(11): S68 doi: 10.1016/j.cgh.2009.08.023
|
| 74 |
Margaret Sutherland, Osama Ahmed, Adnan Zaidi, Shahid Ahmed. Current progress in systemic therapy for biliary tract cancers. Journal of Hepato-Biliary-Pancreatic Sciences 2022; 29(10): 1094 doi: 10.1002/jhbp.939
|
| 75 |
Jose J. G. Marin, Paula Sanchon-Sanchez, Candela Cives-Losada, Sofía del Carmen, Jesús M. González-Santiago, Maria J. Monte, Rocio I. R. Macias. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers 2021; 13(10): 2358 doi: 10.3390/cancers13102358
|
| 76 |
Marianeve Carotenuto, Alessandra Sacco, Laura Forgione, Nicola Normanno. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy 2022; : 200 doi: 10.37349/etat.2022.00079
|
| 77 |
Veronica Porreca, Cristina Barbagallo, Eleonora Corbella, Marco Peres, Michele Stella, Giuseppina Mignogna, Bruno Maras, Marco Ragusa, Carmine Mancone. Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches. Cancers 2024; 16(16): 2889 doi: 10.3390/cancers16162889
|
| 78 |
Wenwei Yang, Yongkun Sun. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. OncoTargets and Therapy 2021; : 1341 doi: 10.2147/OTT.S297643
|
| 79 |
Joachim C. Mertens, Sumera I. Ilyas, Gregory J. Gores. Targeting cholangiocarcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018; 1864(4): 1454 doi: 10.1016/j.bbadis.2017.08.027
|
| 80 |
Jesper B. Andersen, Snorri S. Thorgeirsson. Genetic profiling of intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology 2012; 28(3): 266 doi: 10.1097/MOG.0b013e3283523c7e
|
| 81 |
Brinda Balasubramanian, Simran Venkatraman, Tavan Janvilisri, Tuangporn Suthiphongchai, Siriporn Jitkaew, Jittiyawadee Sripa, Rutaiwan Tohtong. RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach. Pharmaceuticals 2021; 14(9): 898 doi: 10.3390/ph14090898
|
| 82 |
Fatemeh Vatankhah, Neda Salimi, Amirreza Khalaji, Behzad Baradaran. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches. International Immunopharmacology 2023; 114: 109526 doi: 10.1016/j.intimp.2022.109526
|
| 83 |
Maria Maddalena Simile, Paola Bagella, Gianpaolo Vidili, Angela Spanu, Roberto Manetti, Maria Antonietta Seddaiu, Sergio Babudieri, Giordano Madeddu, Pier Andrea Serra, Matteo Altana, Panagiotis Paliogiannis. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina 2019; 55(2): 42 doi: 10.3390/medicina55020042
|